This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

New Hypothesis and New Therapeutic Strategies

John W. Olney, MD; David F. Wozniak, PhD; Nuri B. Farber, MD

Arch Neurol. 1997;54(10):1234-1240.

Abstract
Excessive activation of N-methyl D-aspartate (NMDA) receptors by endogenous glutamate (Glu) causes excitotoxic neuronal degeneration in acute central nervous system injury syndromes such as stroke and trauma. Early attempts to link NMDA receptor hyperactivity (NRHyper) to Alzheimer disease (AD) were stymied by evidence in 3 separate species (mice, rats, and monkeys) that, with advancing age, the NMDA receptor system becomes markedly hypoactive. While this would seem to argue against a role for NMDA receptors in AD, we have recently found in animal studies that, when the NMDA receptor system is rendered markedly hypoactive, a disinhibition syndrome is triggered in which low-grade chronic excitotoxic activity (fueled by acetylcholine and Glu) is unleashed that can cause a widespread pattern of neuronal degeneration resembling that seen in AD. Therefore, we postulate that NMDA receptor hypoactivity (NRHypo) associated with advancing age may have an important contributory role in AD and that the main difference between the aging AD brain and the aging "normal" brain is that a heavier burden of certain adjunctive risk factors may be present in the AD brain that promote the NRHypo state and increase the likelihood that widespread neurodegeneration will occur.

Author Affiliations
From the Department of Psychiatry, Washington University School of Medicine, St Louis, Mo.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Overexpression of Wild-Type Murine Tau Results in Progressive Tauopathy and Neurodegeneration
Adams et al.
Am. J. Pathol. 2009;175:1598-1609.
ABSTRACT | FULL TEXT  

Loss of high-affinity nicotinic receptors increases the vulnerability to excitotoxic lesion and decreases the positive effects of an enriched environment
Zanardi et al.
FASEB J. 2007;21:4028-4037.
ABSTRACT | FULL TEXT  

Reducing Endogenous Tau Ameliorates Amyloid {beta}-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson et al.
Science 2007;316:750-754.
ABSTRACT | FULL TEXT  

A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Reisberg et al.
Arch Neurol 2006;63:49-54.
ABSTRACT | FULL TEXT  

Molecular Determinants of Glycine-Independent Desensitization of NR1/NR2A Receptors
Hu and Zheng
J. Pharmacol. Exp. Ther. 2005;313:563-569.
ABSTRACT | FULL TEXT  

Differential Effects on Current Kinetics by Point Mutations in the lurcher Motif of NR1/NR2A Receptors
Hu and Zheng
J. Pharmacol. Exp. Ther. 2005;312:899-904.
ABSTRACT | FULL TEXT  

Calcium-Dependent Regulation of Cholinergic Cell Phenotype in the Hypothalamus In Vitro
Belousov et al.
J. Neurophysiol. 2002;88:1352-1362.
ABSTRACT | FULL TEXT  

Ontogeny of the N-Methyl-D-Aspartate (NMDA) Receptor System and Susceptibility to Neurotoxicity
Haberny et al.
Toxicol Sci 2002;68:9-17.
ABSTRACT | FULL TEXT  

Glutamate and psychiatric disorders
Tsapakis and Travis
Adv. Psychiatr. Treat. 2002;8:189-197.
FULL TEXT  

alpha 2-Macroglobulin Exposure Reduces Calcium Responses to N-Methyl-D-Aspartate via Low Density Lipoprotein Receptor-related Protein in Cultured Hippocampal Neurons
Qiu et al.
J. Biol. Chem. 2002;277:14458-14466.
ABSTRACT | FULL TEXT  

Urocortin, But Not Urocortin II, Protects Cultured Hippocampal Neurons from Oxidative and Excitotoxic Cell Death via Corticotropin-Releasing Hormone Receptor Type I
Pedersen et al.
J. Neurosci. 2002;22:404-412.
ABSTRACT | FULL TEXT  

Presenilin-1 P264L Knock-In Mutation: Differential Effects on Abeta Production, Amyloid Deposition, and Neuronal Vulnerability
Siman et al.
J. Neurosci. 2000;20:8717-8726.
ABSTRACT | FULL TEXT  

Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: The Cache County Study
Anthony et al.
Neurology 2000;54:2066-2071.
ABSTRACT | FULL TEXT  

Attenuation of the Neuropsychiatric Effects of Ketamine With Lamotrigine: Support for Hyperglutamatergic Effects of N-methyl-D-aspartate Receptor Antagonists
Anand et al.
Arch Gen Psychiatry 2000;57:270-276.
ABSTRACT | FULL TEXT  

Differentiation of Substrate and Nonsubstrate Inhibitors of the High-Affinity, Sodium-Dependent Glutamate Transporters
Koch et al.
Mol. Pharmacol. 1999;56:1095-1104.
ABSTRACT | FULL TEXT  

Potentiation of Excitotoxicity in Transgenic Mice Overexpressing Neuronal Cyclooxygenase-2
Kelley et al.
Am. J. Pathol. 1999;155:995-1004.
ABSTRACT | FULL TEXT  

The Aging Brain: Limitations in Our Knowledge and Future Approaches
Katzman
Arch Neurol 1997;54:1201-1205.
ABSTRACT